Exact Sciences Corporation (EXAS)
$
58.08
+1.52 (2.62%)
Key metrics
Financial statements
Free cash flow per share
1.0392
Market cap
10.7 Billion
Price to sales ratio
3.7986
Debt to equity
1.0519
Current ratio
2.7272
Income quality
-2.0846
Average inventory
169.5 Million
ROE
-0.3642
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Exact Sciences Corporation specializes in cancer screening and diagnostic test products both in the United States and internationally. The company is renowned for its Cologuard test, a non-invasive stool-based DNA screening method that detects DNA and hemoglobin biomarkers linked to colorectal cancer and pre-cancer. In addition, it offers Oncotype DX, a comprehensive gene expression test utilized for breast, prostate, and colon cancers. The Oncotype Test provides tissue profiling that assists in therapy selection for patients with advanced, metastatic, refractory, or recurrent cancers. Furthermore, the Oncotype DX AR-V7 Nucleus Detect Test serves as a liquid-based diagnostic tool specific to advanced-stage prostate cancer. The Oncomap ExTra test gives a detailed biological assessment for certain refractory, rare, or aggressive cancers. Additionally, Exact Sciences plays a role in providing Covid-19 testing services. The company's ongoing research pipeline is focused on improving the performance characteristics of the Cologuard test while also developing blood and other fluid-based tests. The company's stock is identified with the symbol 'EXAS' in the market. The net income ratio is -0.37 reflecting the company's profitability margin, while the income before tax ratio is -0.38 indicating the pre-tax margin. Exact Sciences earned an interest income of -$5,296,000.00 showcasing its financial investments. The diluted EPS is -$5.59 accounting for potential share dilution. The stock is reasonably priced at $58.08 appealing to a broad range of investors. With a mid-range market capitalization of $10,956,095,040.00 the company is a steady performer in the market. Furthermore, the stock has a high average trading volume of 2,630,081.00 indicating strong liquidity and investor interest. As a key player in the Medical - Diagnostics & Research industry, Exact Sciences contributes significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within the healthcare industry. The emphasis on cancer diagnosis and screening positions the company as an essential entity in the ongoing fight against cancer, ensuring it remains at the forefront of diagnostic advancements and patient care solutions.
Is Exact Sciences Corporation (EXAS) a good investment?
Investing in Exact Sciences Corporation (EXAS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Exact Sciences Corporation (EXAS)'s stock forecast?
Analysts predict Exact Sciences Corporation stock to fluctuate between $39.97 (low) and $72.83 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Exact Sciences Corporation's market capitalization?
As of 2025-05-28, Exact Sciences Corporation's market cap is $10,956,095,040, based on 188,638,000 outstanding shares.
How does Exact Sciences Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Exact Sciences Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Exact Sciences Corporation (EXAS) stock?
To buy Exact Sciences Corporation (EXAS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EXAS. Place an order (Market, Limit, etc.).
What is the best time to invest in Exact Sciences Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Exact Sciences Corporation perform in the last earnings report?
Revenue: $2,758,867,000 | EPS: -$5.59 | Growth: 394.69%.
Where can I find Exact Sciences Corporation's investor relations reports?
Visit https://www.exactsciences.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Exact Sciences Corporation?
You can explore historical data from here
What is the all-time high and low for Exact Sciences Corporation stock?
All-time high: $158 (2021-02-16) | All-time low: $29.27 (2022-10-13).
What are the key trends affecting Exact Sciences Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) test, Oncodetect™, in predicting recurrence in stage II–IV colorectal.
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®.
fool.com
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more.
benzinga.com
Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.
zacks.com
Exact Sciences ends the first quarter of 2025 on a solid note.
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.co.
seekingalpha.com
Exact Sciences Corporation. (NASDAQ:EXAS ) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Tycho Peterson - Jefferies Catherine Schulte - Baird Brandon Couillard - Wells Fargo Colleen Babington - Wolfe Research Patrick Donnelly - Citi Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Puneet Souda - Leerink Partners Subu Nambi - Guggenheim Andrew Brackmann - William Blair Luke Sergott - Barclays.
zacks.com
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
zacks.com
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
businesswire.com
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing. The Oncodetect test delivers clear "De.
See all news
